{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:03:25Z","timestamp":1774490605622,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["BF040005"],"award-info":[{"award-number":["BF040005"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Center for HIV and Hepatitis Virology","award":["APP1060433"],"award-info":[{"award-number":["APP1060433"]}]},{"name":"Commonwealth Department of Health and Aged Care, Australia","award":["543139"],"award-info":[{"award-number":["543139"]}]},{"name":"Australia-India Biotechnology Research Fund","award":["APP1062504"],"award-info":[{"award-number":["APP1062504"]}]},{"name":"NHMRC Practitioner Fellowship"},{"name":"NHMRC Senior Research Fellow"},{"name":"Stuart Ralph by a NHMRC Career Development Fellowship"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jviromet.2016.06.012","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T18:27:24Z","timestamp":1467397644000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine"],"prefix":"10.1016","volume":"236","author":[{"given":"L.","family":"Earnest-Silveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Gowans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Torresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2016.06.012_bib0005","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0010","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood-2004-05-1952","article-title":"Uptake and presentation of hepatitis C virus-like particles by human dendritic cells","volume":"105","author":"Barth","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0015","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0016-5085(99)70290-8","article-title":"Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate","volume":"117","author":"Baumert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.26132","article-title":"Chimeric hepatitis B virus\/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine","volume":"57","author":"Beaumont","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jgm.1407","article-title":"Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination","volume":"12","author":"Castellanos","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0030","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses","volume":"88","author":"Chmielewska","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0035","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1016\/j.vaccine.2008.03.032","article-title":"A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection","volume":"26","author":"Chua","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0040","doi-asserted-by":"crossref","first-page":"e47492","DOI":"10.1371\/journal.pone.0047492","article-title":"Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses","volume":"7","author":"Chua","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0045","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/jvh.12163","article-title":"HCV E1E2-MF59vaccine in chronic hepatitis C patients treated with PEG-IFNalpha2a and Ribavirin: a randomized controlled trial","volume":"21","author":"Colombatto","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1053\/j.gastro.2010.05.077","article-title":"Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins","volume":"139","author":"Dahari","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0055","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0060","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/hep.28428","article-title":"Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge","volume":"63","author":"Desombere","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0065","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.000493","article-title":"Characterisation of a hepatitis C virus like particle vaccine produced in a human hepatocyte-derived cell line","author":"Earnest-Silveira","year":"2016","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0070","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0080","doi-asserted-by":"crossref","first-page":"94ra71","DOI":"10.1126\/scitranslmed.3002330","article-title":"A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques","volume":"3","author":"Garrone","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0085","doi-asserted-by":"crossref","first-page":"10999","DOI":"10.1128\/JVI.00526-10","article-title":"Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture","volume":"84","author":"Gastaminza","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0090","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/gt.2015.86","article-title":"Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs","volume":"23","author":"Grubor-Bauk","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0100","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1128\/JVI.00803-15","article-title":"A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-Cell responses in mice","volume":"89","author":"Gummow","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2011.06.009","article-title":"A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C","volume":"141","author":"Habersetzer","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.epidem.2008.10.002","article-title":"Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users","volume":"1","author":"Hahn","year":"2009","journal-title":"Epidemics"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0120","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct propertires and biological functions","volume":"78","author":"Keck","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0130","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0135","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0140","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2012.02.070","article-title":"Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination","volume":"30","author":"Klade","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0145","doi-asserted-by":"crossref","first-page":"e1000762","DOI":"10.1371\/journal.ppat.1000762","article-title":"The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule","volume":"6","author":"Krey","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0150","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.vaccine.2015.11.061","article-title":"Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: a novel VLP prime-adenovirus boost strategy","volume":"34","author":"Kumar","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0155","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/j.gastro.2004.06.015","article-title":"High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection","volume":"127","author":"Lauer","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0160","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.1131929100","article-title":"Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection","volume":"100","author":"Murata","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 2","key":"10.1016\/j.jviromet.2016.06.012_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1478-3231.2011.02537.x","article-title":"The global health burden of hepatitis C virus infection","volume":"31","author":"Negro","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0170","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.80.5.2418-2428.2006","article-title":"Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients","volume":"80","author":"Nielsen","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0175","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nbt.2009.01.001","article-title":"Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies","volume":"25","author":"Patient","year":"2009","journal-title":"New Biotechnol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0180","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.21319","article-title":"CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus","volume":"44","author":"Puig","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0185","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1073\/pnas.93.5.1759","article-title":"A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells","volume":"93","author":"Rosa","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0190","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0195","doi-asserted-by":"crossref","first-page":"e80216","DOI":"10.1371\/journal.pone.0080216","article-title":"High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study","volume":"8","author":"Sacks-Davis","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.jviromet.2016.06.012_bib0200","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0168-8278(09)60045-3","article-title":"A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C","volume":"50","author":"Sallberg","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0205","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/14712590902988444","article-title":"DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target","volume":"9","author":"Sallberg","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1084\/jem.20100388","article-title":"Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence","volume":"209","author":"Schulze Zur Wiesch","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0215","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12916-015-0440-2","article-title":"The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments","volume":"13","author":"Scott","year":"2015","journal-title":"BMC Med."},{"issue":"Suppl. 1","key":"10.1016\/j.jviromet.2016.06.012_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jgh.12677","article-title":"Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia","volume":"29","author":"Sievert","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0225","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1086\/505714","article-title":"Differential antigenic hierarchy associated with spontaneous Recovery from hepatitis C virus infection: implications for vaccine design","volume":"194","author":"Smyk-Pearson","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0230","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1128\/JVI.78.17.9030-9040.2004","article-title":"Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C","volume":"78","author":"Steinmann","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0235","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0240","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the Hepatitis C Virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clim.2008.04.002","article-title":"Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response","volume":"128","author":"Thammanichanond","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0250","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.icb.7100021","article-title":"Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes","volume":"85","author":"Torresi","year":"2007","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jviromet.2016.06.012_bib0255","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep.21538","article-title":"A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus","volume":"45","author":"Torresi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jviromet.2016.06.012_bib0260","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s007050050306","article-title":"Molecular cloning of an Australian isolate of hepatitis C virus","volume":"143","author":"Trowbridge","year":"1998","journal-title":"Arch. Virol"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093416301501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093416301501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T06:13:52Z","timestamp":1600841632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093416301501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":52,"alternative-id":["S0166093416301501"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2016.06.012","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2016.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}